Literature DB >> 36098853

Serum-soluble ST2 and systemic sclerosis arthropathy.

Amalia Colalillo1, Chiara Pellicano1, Edoardo Rosato2.   

Abstract

Interleukin (IL)33 and its receptor ST2 have been involved in the pathogenesis of several conditions, including arthritis. The aim of the study was to evaluate the association between IL33 or soluble ST2 (sST2) serum levels and systemic sclerosis (SSc) articular involvement. IL33 and sST2 serum levels were measured in 64 SSc patients and 24 HC matched for sex and age. Articular involvement assessed by using Disease Activity Score 28 based on erythrocyte sedimentation rate (DAS28-ESR), presence of tendon friction rubs (TFRs) and finger-to-palm (FTP) distance. sST2 serum levels were significantly higher in SSc patients with DAS28-ESR > 3.2 than in SSc patients with DAS28-ESR⩽3.2 [9726.1 (IQR 7746.5 - 14,953.5) pg/mL vs 7611.7 (IQR 5162.6 -11,036.7) pg/mL; p < 0.05]. sST2 serum levels were significantly higher in SSc patients with TFRs compared to SSc patients without TFRs [9726.1 (IQR 7746.5 - 14,953.5) pg/mL vs 7426.4 (IQR 5145.9 - 10,593.5) pg/mL; p < 0.01] and in SSc patients with FTP ≥ 1 cm compared to SSc patients with FTP < 1 cm [9683.7 (IQR 8067.2 - 16,387.6) pg/mL vs 7679.1 (IQR 5246.1 - 11,472.2) pg/mL; p < 0.05]. No significant association was observed between IL33 and DAS28-ESR, TFRs and FTP. A slightly positive linear correlation was found between sST2 and Disease Activity Index (r = 0.294, p < 0.05) and Disease Severity Scale (r = 0.265, p < 0.05). sST2 serum levels were positively correlated with DAS28-ESR (r = 0.371, p < 0.01). Elevated sST2 serum levels were associated with higher articular disease activity, TFRs and hand dysfunction, suggesting that sST2 might have a role in the pathogenesis of SSc articular involvement. Key Points • In SSc patients elevated serum levels of sST2 were associated with higher articular disease activity • High serum levels of sST2 were reported in SSc patients with TFRs and hand dysfunction • sST2 might have a role in the pathogenesis of SSc articular involvement.
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  IL33; Joint; Systemic sclerosis; Tendon friction rubs; sST2

Year:  2022        PMID: 36098853     DOI: 10.1007/s10067-022-06367-w

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  21 in total

Review 1.  IL-33/ST2 Axis in Organ Fibrosis.

Authors:  Ourania S Kotsiou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Front Immunol       Date:  2018-10-24       Impact factor: 7.561

2.  Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.

Authors:  Britta Maurer; Nicole Graf; Beat A Michel; Ulf Müller-Ladner; László Czirják; Christopher P Denton; Alan Tyndall; Carola Metzig; Vivian Lanius; Dinesh Khanna; Oliver Distler
Journal:  Ann Rheum Dis       Date:  2014-06-30       Impact factor: 19.103

3.  Reliability and validity of the delta finger-to-palm (FTP), a new measure of finger range of motion in systemic sclerosis.

Authors:  Kathryn S Torok; Nancy A Baker; Mary Lucas; Robyn T Domsic; Robert Boudreau; Thomas A Medsger
Journal:  Clin Exp Rheumatol       Date:  2010-06-10       Impact factor: 4.473

4.  Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.

Authors:  Wanlong Wu; Suzana Jordan; Mike Oliver Becker; Rucsandra Dobrota; Britta Maurer; Håvard Fretheim; Shuang Ye; Elise Siegert; Yannick Allanore; Anna-Maria Hoffmann-Vold; Oliver Distler
Journal:  Ann Rheum Dis       Date:  2018-06-06       Impact factor: 19.103

Review 5.  The role of the IL-33/ST2 axis in autoimmune disorders: Friend or foe?

Authors:  Xiuxing Liu; Yichen Xiao; Yuan Pan; He Li; Song Guo Zheng; Wenru Su
Journal:  Cytokine Growth Factor Rev       Date:  2019-04-03       Impact factor: 7.638

Review 6.  Musculoskeletal hand involvement in systemic sclerosis.

Authors:  Robert David Sandler; Marco Matucci-Cerinic; Michael Hughes
Journal:  Semin Arthritis Rheum       Date:  2019-11-09       Impact factor: 5.532

7.  Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study.

Authors:  Jérôme Avouac; Ulrich A Walker; Eric Hachulla; Gabriela Riemekasten; Giovanna Cuomo; Patricia E Carreira; Paola Caramaschi; Lidia P Ananieva; Marco Matucci-Cerinic; Laszlo Czirjak; Christopher Denton; Ulf Müller Ladner; Yannick Allanore
Journal:  Ann Rheum Dis       Date:  2014-08-27       Impact factor: 19.103

Review 8.  Role of IL-33/ST2 signaling pathway in systemic sclerosis and other fibrotic diseases.

Authors:  Dan Xu; Mark Barbour; Hui-Rong Jiang; Rong Mu
Journal:  Clin Exp Rheumatol       Date:  2019-09-03       Impact factor: 4.473

9.  Sensitivity to change of joint count composite indices in 72 patients with systemic sclerosis.

Authors:  Veronika Lóránd; Gabriella Nagy; Zsófia Bálint; Dalma Komjáti; Tünde Minier; Gábor Kumánovics; Nelli Farkas; Ingo H Tarner; Ulf Müller-Ladner; László Czirják; Cecília Varjú
Journal:  Clin Exp Rheumatol       Date:  2021-03-17       Impact factor: 4.473

Review 10.  Interleukin-33 in Systemic Sclerosis: Expression and Pathogenesis.

Authors:  Liya Li; Honglin Zhu; Xiaoxia Zuo
Journal:  Front Immunol       Date:  2018-11-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.